OKYO Pharma Accelerates Urcosimod Development for Neuropathic Corneal Pain

The latest announcement is out from OKYO Pharma Limited Sponsored ADR ( (OKYO) ).

On April 30, 2025, OKYO Pharma Limited announced its decision to accelerate the clinical development of urcosimod for treating neuropathic corneal pain (NCP) following the early closure of its Phase 2 trial. The trial, initially planned to include 48 patients, was closed early after 17 patients completed it, allowing the company to access and analyze the masked data. This strategic move aims to expedite discussions with the FDA and advance the drug’s development program, potentially expanding to a multicenter trial due to significant interest from patients. The company also plans to arrange for the continued compassionate use of urcosimod for trial participants, subject to FDA approval. This development underscores OKYO Pharma’s commitment to addressing the unmet need for FDA-approved treatments for NCP, a condition characterized by severe, chronic pain without existing approved therapies.

Spark’s Take on OKYO Stock

According to Spark, TipRanks’ AI Analyst, OKYO is a Underperform.

OKYO Pharma Limited’s stock is primarily affected by its significant financial challenges, including no revenue generation and negative equity. Technical analysis provides a neutral to slightly bearish outlook, while traditional valuation metrics are not applicable, reflecting typical biotech industry characteristics.

To see Spark’s full report on OKYO stock, click here.

More about OKYO Pharma Limited Sponsored ADR

OKYO Pharma Limited is a clinical stage biopharmaceutical company listed on the NASDAQ Capital Market, focusing on developing innovative therapies for neuropathic corneal pain and dry eye disease. The company is engaged in discovering and developing novel molecules to treat these conditions, with its primary product being urcosimod, a drug candidate designed to address inflammation and pain in ocular diseases.

YTD Price Performance: 37.17%

Average Trading Volume: 108,966

Technical Sentiment Signal: Sell

Current Market Cap: $52.52M

Learn more about OKYO stock on TipRanks’ Stock Analysis page.